빈서엑스 파마 (VINC) 주가

빈서엑스 파마(VINC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.01 (+0.00%), 시가총액 $0.00B, 52주 최저~최고 $0.01 ~ $0.07.

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which

핵심 지표

• 현재가: $0.01 (+0.00%)
• 시가총액: $0.00B
• 52주 최저~최고: $0.01 ~ $0.07
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

빈서엑스 파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

빈서엑스 파마 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.03
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문